MedRx Co., Ltd (TYO:4586)

Japan flag Japan · Delayed Price · Currency is JPY
99.00
-8.00 (-7.48%)
Mar 9, 2026, 3:30 PM JST
19.28%
Market Cap 5.88B
Revenue (ttm) 128.00M
Net Income (ttm) -937.00M
Shares Out 59.37M
EPS (ttm) -17.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,034,400
Average Volume 2,015,350
Open 100.00
Previous Close 107.00
Day's Range 97.00 - 102.00
52-Week Range 55.00 - 225.00
Beta 0.76
RSI 49.35
Earnings Date Feb 13, 2026

About MedRx

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which has completed phase Ib clinical trials for the treatment of spastic paralysis; MRX-9FLT that... [Read more]

Sector Healthcare
Founded 2002
Employees 22
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4586
Full Company Profile

Financial Performance

In 2025, MedRx's revenue was 128.00 million, a decrease of -50.19% compared to the previous year's 257.00 million. Losses were -937.00 million, 16.3% more than in 2024.

Financial Statements

News

There is no news available yet.